Genprex Yönetim

Yönetim kriter kontrolleri 3/4

Genprex CEO'su Ryan Confer, Sep2016 tarihinde atandı, in görev süresi 8.17 yıldır. şirketin hisselerinin 0.19% doğrudan sahiptir ve bu hisselerin değeri $ 14.41K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.2 yıl ve 4.3 yıldır.

Anahtar bilgiler

Ryan Confer

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresi8.2yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi3.2yrs
Yönetim Kurulu ortalama görev süresi4.3yrs

Son yönetim güncellemeleri

Recent updates

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Aug 16
Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Jan 31
Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Oct 12
Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Aug 15

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Jun 14
We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Feb 09
Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex: Limited Clinical Data To Justify Risk

Nov 19

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Oct 27
We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Jun 11
Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

May 05

Genprex' stock jumps after corporate update

Feb 01

Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials

Jan 13

Genprex completes manufacturing scale-up of lung cancer therapy

Dec 22

CEO Tazminat Analizi

Ryan Confer'un ücretlendirmesi Genprex'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$28m

Dec 31 2023n/an/a

-US$31m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$30m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$1mUS$393k

-US$24m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$21m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$1mUS$345k

-US$21m

Sep 30 2021n/an/a

-US$19m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$1mUS$351k

-US$18m

Sep 30 2020n/an/a

-US$15m

Jun 30 2020n/an/a

-US$15m

Mar 31 2020n/an/a

-US$14m

Dec 31 2019US$1mUS$300k

-US$11m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$11m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$2mUS$225k

-US$12m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$8m

Mar 31 2018n/an/a

-US$3m

Dec 31 2017US$585kUS$180k

-US$3m

Tazminat ve Piyasa: Ryan şirketinin toplam tazminatının US pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: Ryan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Ryan Confer (42 yo)

8.2yrs

Görev süresi

US$1,135,943

Tazminat

Mr. Ryan M. Confer, M.S. has been the Chief Financial Officer of Genprex, Inc. since September 2016 and serves as its Chief Executive Officer, President and Director since May 08, 2024. Mr. Confer has serv...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Mark Berger
Chief Medical Officer3.2yrsUS$947.11k0.048%
$ 3.7k
Ryan Confer
President8.2yrsUS$1.14m0.19%
$ 14.4k
David Schloss
Senior Vice President of Human Resources2.8yrsVeri yokVeri yok
Thomas Gallagher
Senior Vice President of Intellectual Property & Licensing4.2yrsVeri yokVeri yok
Suzanne Thornton-Jones
Senior Vice President of Regulatory Affairs & Quality1.3yrsVeri yokVeri yok
Jack Roth
Chairman of Scientific & Medical Advisory Boardno dataVeri yokVeri yok

3.2yrs

Ortalama Görev Süresi

Deneyimli Yönetim: GNPX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.2 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Ryan Confer
Presidentless than a yearUS$1.14m0.19%
$ 14.4k
Jack Roth
Chairman of Scientific & Medical Advisory Boardno dataVeri yokVeri yok
Brent Longnecker
Independent Director4.7yrsUS$161.61k0.024%
$ 1.9k
James E. Rothman
Strategic Advisor to the Board of Directors12.3yrsVeri yokVeri yok
Pasi Antero Janne
Member of Scientific & Medical Advisory Boardno dataVeri yokVeri yok
George Peoples
Member of Clinical Advisory Board3.8yrsVeri yokVeri yok
Shu Kam Mok
Member of Scientific & Medical Advisory Boardno dataVeri yokVeri yok
George Simon
Member of Scientific & Medical Advisory Boardno dataVeri yokVeri yok
William Wilson
Independent Director4.7yrsUS$151.16k0%
$ 0
Jose Antonio Toscano
Independent Non-Executive Chairman4.7yrsUS$161.61k0%
$ 0
George Gittes
Member of Scientific Advisory Board4yrsVeri yokVeri yok
Michael Morse
Member of Clinical Advisory Board3.8yrsVeri yokVeri yok

4.3yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: GNPX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).